Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
(R)-Equol has a Kis of 15.4 nM for ERβ and 27.4 nM for ERβ, making it an agonist for both receptors [1]. The invasive ability of MDA-MB-231 cells was inhibited by (R)-Equol in a dose-dependent manner; this impact was noteworthy even at the highest tested concentration of 50 μM. 50 μM (R)-equol decreased invasion by 62% (p=0.009 compared to untreated cells) after 48 hours of exposure to (R)-equol. Following treatment with 50 μM (R)-Equol, there was a substantial down-regulation of matrix metalloproteinase-2 (MMP-2) expression (p=0.035)[2].
|
---|---|
ln Vivo |
Over time, palpable tumors were considerably less common in animals fed (R)-equol than in controls (P=0.002). Additionally, compared to rats fed S-(-)equol, the number of palpable tumors produced per rat in the (R)-equol-fed group was considerably fewer (P=0.008). There were 43% fewer tumors in animals fed (R)-equol than in controls, a highly significant difference (P=0.004). When comparing animals fed (R)-equol to the control group, the number of tumors/tumor-bearing animals was considerably lower (3.3±0.4 vs. 5.5±0.5, P=0.004). Rats fed on equol had a considerably lower mean (±SEM) tumor weight per animal at necropsy (5.3±1.1 mg) than the controls (9.9±1.4 mg) (P= 0.04). There was a significant increase in tumor latency (P=0.003) after feeding the (R)-equol diet [3].
|
References |
[1]. Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
[2]. Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50. [3]. Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis. 2010 May;31(5):886-93 |
Molecular Formula |
C15H14O3
|
---|---|
Molecular Weight |
242.26986
|
CAS # |
221054-79-1
|
Related CAS # |
(-)-(S)-Equol;531-95-3;(±)-Equol;94105-90-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
OC1=CC=C2C[C@H](C3=CC=C(O)C=C3)COC2=C1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~412.76 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.1276 mL | 20.6381 mL | 41.2763 mL | |
5 mM | 0.8255 mL | 4.1276 mL | 8.2553 mL | |
10 mM | 0.4128 mL | 2.0638 mL | 4.1276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.